Dr. Jin Google Scholar Citations
2026
Chen, H.; Dutta, R. P.; Li, Z.; Zhong, Y.; Ma, A.; Park, K. S.; Kottur, J.; Park, A.; Babault, N.; Wang, K.; Wang, D.; Xiong, Y.; Kaniskan, H. Ü.; Luo, M.; Parekh, S.; Jin, J.*, “Discovery of a Potent, Selective, and In Vivo Efficacious Covalent Inhibitor for Lysine Methyltransferase SETD8”, Journal of Medicinal Chemistry, 2026, 69(4), 4255-4269.
Yim, H.; Song, X.; Zhong, Y.; Hu, J.; Xiong, Y.; Jin, J.*, “Discovery of KRAS-G12D degraders via exploration of various E3 ligases”, European Journal of Medicinal Chemistry, 2026, 307, 118635.
Xia, Z.; Yang, X.; Samovich, S. N.; Tyurina, Y. Y.; Tyurin, V. A.; Kon, N.; Zhang, J.; Jiang, X.; Stockwell, B. R.; Jin, J.; Bayir, H.; Kagan, V. E.; Gu, W.*, “A GPX1–OSBPL8 Axis Mediates Noncanonical In Vivo Ferroptosis and Cancer Growth Suppression”, Cell , 2026, Feb 19, doi: 10.1016/j.cell.2026.01.009. PMCID: PMC12927606.
Gelles, J. D.; Chen, Y.; Luna-Vargas, M. P. A.; Viacava Follis, A.; Al Noman, M. A.; Kabir, M.; Bayiokos, S. G.; Mohammed, J. N.; Sebastian, T. M.; Pham, N. D.; Shi, Y.; Jin, J.; Kriwacki, R. W.; Chipuk, J. E.*, “A gated hydrophobic funnel within BAX binds bioactive lipids to potentiate pro-apoptotic function”, Nature Communications , 2026, Feb 25, doi: 10.1038/s41467-026-69836-9.
Wang, Y.; Xiong, Y.; Liu, S.; Bao, L.; Qiu, X.; Korboukh, I.; Song, X.; Toffessi Tcheuyap, V.; Wu, S.; Chen, M.; Brugarolas, J.; Jin, J.; Wang, Y.; Luo, W.*, “HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer”, Cell Reports Medicine, 2026, Feb 18, 102630. doi: 10.1016/j.xcrm.2026.102630.
Yi, Y.; Li, Y.; Wang, R.; Yu, X.; Liu, Q.; Yum, C.; Zhang, Y.; Qiao, Y.; Szczepanski, A.; Wu, S.; Li, Q.; Fazli, L.; Shen, J.; Wang, X.; Li, X.; Mu, P.; Schaeffer, E. M.; Hundley, H. A.; Niu, H.; Chinnaiyan, A. M.; Wang, L.; Shi, J.; Jin, J.; Dong, X.; Zhao, W.; Chen, K.; Cao, Q.*, “A dual role of EZH2 in regulating A-to-I RNA editing and mRNA stability through ADAR”, Nature Communications, 2026, find PMID.
Yi, Y.; Fry, J.; Yum, C.; Wang, R.; Wu, S.; Narayan, S.; Liu, Q.; Zhang, X.; Oo, H. Z.; Xie, N.; Li, Y.; Gao, X.; Yu, X.; Hu, X.; Li, Q.; Keseroglu, K.; Özbudak, E. M.; Abdulkadir, S. A.; Chen, K.; Jin, J.; Zhao, J. C.; Dong, X.; Arango, D.; Yang, R.; Cao, Q.*, “EZH2 crosstalk with RNA methylation promotes prostate cancer progression through modulation of the m6A autoregulation pathway” Journal of Clinical Investigation, 2026, 136(2). doi: 10.1172/JCI195840. PMCID: PMC12807473.
2025 (showing 16 out of 34 publications)
Hosseini, A.; Qiu, X.; Xiong, Y.*; Chiang, K. H. N.; Catlett, J.; Kaltheuner, I.; Deng, Z.; Ghosh, S.; Shi, Y.*; Jin, J.* “Discovery of an LSD1 PROTAC Degrader”, Proceedings of the National Academy Sciences of the United States of America (PNAS), 2025, 122(20):e2425812122. PMCID: PMC12107161.
Qian, C.; Wang, Z.; Xiong, Y.; Zhang, D.; Zhong, Y.;Inuzuka, H.; Qi, Y.; Xie, L.; Chen, X.; Wei, W.* ; Jin, J.* , “Harnessing the Deubiquitinase USP1 for Targeted Protein Stabilization”. Journal of the American Chemical Society , 2025, 147(17):14564-14573. PMCID: PMC12077936.
Zhong, Y.; Kim, H. S.; Qian, C.; Xie, L.; Chen, X.; Xiong, Y.; Hu, J.; Chen, M.; Guccione, E.; Shen, Y.*; Jin, J.* , “Discovery of A Potent and Selective Protein Arginine Methyltransferase 5 (PRMT5) PROTAC Degrader”. Journal of Medicinal Chemistry, 2025, 68(8): 8543–8563. PMCID: PMC12080994.
Deng, Z.; Catlett, J.; Lee, Y.; Wu, Q.; Xu, Z.; Xie, L.; Chen, X.; Xiong, Y.; Kaniskan, H. U.*; Jin, J.*; “Harnessing the SPOP E3 Ubiquitin Ligase via Bridged Proteolysis Targeting Chimera (PROTAC) Strategy for Targeted Protein Degradation”, Journal of Medicinal Chemistry, 2025, 68(8):8634-8647. PMCID: PMC12043353.
Yim, H.; Sun, R.; Xu, Z.; Kim, H. S.; Kim, M.; Cao, T.; Xie, L.; Chen, X.; Kaniskan, H. U.*; Jin, J.*; “Discovery of the First-in-class DOT1L PROTAC Degrader” European Journal of Medicinal Chemistry , 2025, 291:117595. PMCID: PMC12045715.
Qian,C.; Lee,Y.; Han,Y.; Zhong,Y.; Zhou,J.; Hrit, J.; Xie,L.; Chen, Q.; Kaniskan, H. U.; Chen, X.; Rothbart, S.; Cheng, X.; Xiong, Y.*; Jin, J.* , “Structure-activity Relationship Studies of DNA Methyltransferase 1 (DNMT1) Monovalent Degraders”. Journal of Medicinal Chemistry, 2025, 68(3):2903–2919. PMCID: PMC11932022.
Deng, Z; Chen, L; Qian, C; Liu,J; Wu,Q; Song,X; Xiong,Y.; Wang, Z; Hu, X; Inuzuka, H; Zhong, Y; Lin; Y; Pham, N.D.; Shi,Y; Wei ;W.*; Jin,J.* Angewandte Chemie International Edition, “The First-in-class Deubiquitinase-targeting Chimera Stabilizes and Activates cGAS.”,2025, 64(3):e202415168. PMCID: PMC11738674.
Kabir. M.; Hu, X. Martin, T. C.; Pokushalov, D.; Kim, Y. J.; Chen, Y.; Zhong, Y.; Wu, Q; Chipuk, J. Y.; Shi, Y; Xiong, Y.; Gu, W.; Parsons, R. E.; and Jin, J.* , “Harnessing the TAF1 Acetyltransferase for Targeted Acetylation of the Tumor Suppressor p53”, Advanced Science, 2025, 12(7):e2413377. PMCID: PMC11831463.
Xu, Z.; Pokushalov, D.; Kabir, M.; Lee, Y.; Chattopadhyay, M.; Jenkins, E. C.; Choo, C.; Kaniskan, H. Ü.; Germain, D.*; Jin, J.*“Targeting the Mitochondrial Protease ClpP for Anticancer Therapy”. Journal of Medicinal Chemistry, 2025, 68(20):21377-21393. PMID: 41032690.
Chen, L.; Deng, Z.; Xiong, Y.; Liu, J.; Huang, D.; Wang, J.; Chen, Y.; Inuzuka, H.; Xie, L.; Chen, X.; Jin, J.*; Wei, W.* “Deubiquitinase-Targeting Chimeras Mediated Stabilization of Tumor Suppressive E3 Ligase Proteins as a Strategy for Cancer Therapy”. Journal of the American Chemical Society, 2025, 147(33):29875-29883. PMCID: PMC12395470.
Hu, X.; Graciano, K.; Hu, J.; Liu, C.; Zhang, J.; Xie, L.; Chen, X.; Xiong, Y.; Jin, J.*; Xu, J.* “Discovery of the first-in-class Aurora B kinase selective degrader” European Journal of Medicinal Chemistry, 2025, 298: 118006. PMCID: PMC12379206.
Wang, Z.; Qian, C.; Xiong, Y.; Zhang, D.; Inuzuka, H.; Zhong, Y.; Xie, L.; Chen, X.; Jin, J.*; Wei, W.*, “USP28-Based Deubiquitinase-Targeting Chimeras for Cancer Treatment”, Journal of the American Chemical Society,2025, 147(16):13754–13763. PMCID: PMC12105324.
Zhu, Z.; Chen, H.; Qiu, X.; Kaniskan, H. Ü.; Xie, L.; Chen, X.; Jin, J.*; Liu, P.* “(GGAA)3-based TF-PROTACs enable targeted degradation of ETV6 to inhibit Ewing sarcoma growth”, Journal of the American Chemical Society, 2025, 147(16):13396–13404. PMID: 40215343.
Teichman , E. M.; Hu , J.; in, H.; Fisher, R. F.; Blando, A.; Hu, X.; Kaniskan , H. U; Montgomery, S. E.; Cai, M.; Parise, L.; Wang, J.; Russo, S.; Han, M.*; Jin , J.*; Morel, C.* , “Design and validation of novel brain-penetrant HCN channel inhibitors to ameliorate social stress-induced susceptible phenotype”. Molecular Psychiatry, 2025, 30(9):3937-3950.PMCID: PMC12339378.
Xie, L; Sheehy, RN; Muneer, A; Xiong, Y; Wrobel, JA; Zhang, F; Park, KS; Velez, J; Liu, J; Luo, YJ; Asrican, B; Dong, P; Li, YD; Damian, C; Quintanilla, L; Li, Y; Xu, C; Deshmukh, M; Coleman, LG Jr; Ming, GL; Song, H; Wen, Z; Jin, J*; Song, J*; Chen, X*. “Development of a brain-penetrant G9a methylase inhibitor to target Alzheimer’s disease-associated proteopathology”. Nature Communication, 2025. 16(1):4222. PMCID: PMC12056044.
Martinez, Criseyda; Xiong, Yan; Bartkowski, Alison; Harada, Ibuki; Ren, Xiaoxiao; Byerly, Jessica; Port, Elisa; Jian Jin*; Irie, Hanna*. “A PROTAC degrader suppresses oncogenic functions of PTK6 inducing apoptosis of breast cancer cells”, Cell Chemical Biology, 2025, 32(2):255-266.E8. PMCID: PMC11845306.
2024 (showing 10 out of 15 publications)
Inuzuka, H; Qian, Chao; Qi,Y; Xiong, Y; Wang, C;Wang,Z; Zhang, D;Zhang, C; Jin, J*; Wei, W*; ACS Pharmacology & Translational Science , “Targeted Degradation of Receptor-Interacting Protein Kinase 1 to Modulate the Necroptosis Pathway”, 2024, 7, 3518-3526. PMCID: PMC11555510.
Xue Z; Qin L; Xuan H.; Luo K.; Huang M; Xie, L; Su, Y.; Xu L; Harsh, J.; Dale, B.; Shi, X.; Chen, X.; Kaniskan, HÜ.; Jin, J*., Wen, H.*, Science Advances, “A potent and selective ENL degrader suppresses oncogenic gene expression and leukemia progression”. 2024 Aug 30;10(35).eado1432. PMID:39196923. PMCID: PMC11352836
Hu,X; Kabir, M; Lin, Y; Xiong Y; Parsons, R; Gu, W; Jin, J*. Journal of Medicinal Chemistry “Design, Synthesis, and Evaluation of p53Y220C Acetylation Targeting Chimeras (AceTACs)”, , August, 2024, 67, 14633−14648 PMID:39169826.
Wang, S, E.; Xiong, Y.;Jang, M, A,; Park, K, S.; Donahue, M.; Velez J.; Jin J.*; Jiang, Y, H.*, Molecular Therapy, “Newly developed oral bioavailable EHMT2 inhibitor as a potential epigenetic therapy for Prader-Willi syndrome”, 2024 Aug 7;32(8):2662-2675. PMID: 38796700;.doi: https://doi.org/doi:10.1016/j.ymthe.2024.05.034
Kabir, M.; Qin, L.; Luo, K.; Xiong, Y.; Sidi, R. A.; Park, K.-S.*; Jin, J.*, “Discovery and characterization of a novel Cereblon-recruiting PRC1 bridged PROTAC degrader.” Journal of Medicinal Chemistry. 2024, 67:6880-6892. PMID: 38607318.
Velez, J.; Han, Y.; Yim, H.; Yang, P.; Deng, Z.; Park, K.-s.; Kabir, M.; Kaniskan, H. Ü.; Xiong, Y.*; Jin, J.*, Discovery of the first-in-class G9a/GLP PROTAC degrader. Journal of Medicinal Chemistry. 2024, 67(8):6397-6409. PMID: 28602846.
Liu, J; Hu, X.; Luo, K; Xiong, Y; Chen, L.; Wang, Z.; Inuzuka, H.; Qian, C.; Yu, X.; Xie, L.; Muneer, A.; Zhang, D.; Paulo, J. A.; Chen, X.; Jin, J.*; Wei, W.*, Journal of the American Chemical Society“, USP7-based deubiquitinase-targeting chimeras stabilize AMPK.” 2024, 146, 16, 11507–11514; PMID: 38597345.
Xiong, Y.; Greschik, H.; Johansson, C.; Seifert, L.; Gamble, V.; Park, K.-s.; Fagan, V.; Li, F.; Chau, I.; Vedadi, M.; Arrowsmith, C. H.; Brennan, P.; Fedorov, O.; Jung, M.; Farnie, G.; Liu, J.; Oppermann, U. *; Schüle, R. *; Jin, J. *, Discovery of a potent, selective, and cell-active SPIN1 inhibitor. Journal of Medicinal Chemistry. 2024, 67(7):5837-5853. PMID: 38533580.
Wang, Z.; Zhang, D.; Qiu, X.; Inuzuka, H.; Xiong, Y.; Liu, J.; Chen, L.; Chen, H.; Xie, L.; Kaniskan, H. Ü.; Chen, X.; Jin, J. *; Wei, W. *, Journal of the American Chemical Society . “Structurally specific Z-DNA proteolysis targeting chimera enables targeted degradation of adenosine deaminase acting on RNA”, 2024, 146 (11): 7584-7593. PMID: 38469801.
Velez, J.; Dale, B.; Park, K.-S.; Kaniskan, H. Ü.; Yu, X. *; Jin, J. *, “Discovery of a novel, highly potent EZH2 PROTAC degrader for targeting non-canonical oncogenic functions of EZH2”. European Journal of Medicinal Chemistry, 2024, 267, 116154. PMID: 38602846.,
2023 (showing 12 out of 24 publications)
Dang, F.; Bai, L.; Dong, J.; Hu, X.; Wang, J.; Paulo, J. A.; Xiong, Y.; Liang, X.; Sun, Y.; Chen, Y.; Guo, M.; Wang, X.; Huang, Z.; Inuzuka, H.; Chen, L.; Chu, C.; Liu, J.; Zhang, T.; Rezaeian, A.-H.; Liu, J.; Kaniskan, H. Ü.; Zhong, B.; Zhang, J.; Letko, M.; Jin, J. *; Lan, K. *; Wei, W. *, USP2 inhibition prevents infection with ACE2-dependent coronaviruses in vitro and is protective against SARS-CoV-2 in mice. Science Translational Medicine. 2023, 15 (725): eadh7668. PMID: 38055802.
Yu, X.; Li, D.; Kottur, J.; Kim, H. S.; Herring, L. E.; Yu, Y.; Xie, L.; Hu, X.; Chen, X.; Cai, L.; Liu, J.; Aggarwal, A. K.; Wang, G. G. *; Jin, J.*, Discovery of Potent and Selective WDR5 Proteolysis Targeting Chimeras as Potential Therapeutics for Pancreatic Cancer. Journal of Medicinal Chemistry. 2023, 66(23): 16168–16186. PMID: 38019706.
Kabir, M.; Sun, N.; Hu, X.; Martin, T. C.; Yi, J.; Zhong, Y.; Xiong, Y.; Kaniskan, H. Ü.; Gu, W.; Parsons, R.; Jin, J.*; Acetylation Targeting Chimera Enables Acetylation of the Tumor Suppressor p53. Journal of the American Chemical Society 2023, 145(27):14932-14944. PMID: 37365684.
Wang Z.; Liu J.; Qiu X.; Zhang D.; Inuzuka H.; Chen L.; Chen H.; Xie L.; Kaniskan HÜ.; Chen X.; Jin J.* ; Wei W.* , Methylated Nucleotide-Based Proteolysis-Targeting Chimera Enables Targeted Degradation of Methyl-CpG-Binding Protein 2. Journal of the American Chemical Society . 2023, 145(40): 21871–21878. PMID: 37774414.
Velez, J.; Kaniskan, H. Ü.*; Jin, J.*; Recent advances in developing degraders & inhibitors of lysine methyltransferases. Current Opinion in Chemical Biology, 2023, 76:102356. PMID: 37379717.
Kabir, M.; Yu, X.; Kaniskan, H. Ü.*; Jin, J.*; Chemically induced degradation of epigenetic targets. Chemical Society Reviews, 2023, 52(13):4313-4342. PMID: 37314393.
Zhao, N.; Ho, J. S. Y.; Meng, F.; Zheng, S.; Kurland, A. P.; Tian, L.; Rea-Moreno, M.; Song, X.; Seo, J. S.; Kaniskan, H. Ü.; Te Velthuis, A. J. W.; Tortorella, D.; Chen, Y. W.; Johnson, J. R.; Jin, J.*; Marazzi, I.*; Generation of host-directed and virus-specific antivirals using targeted protein degradation promoted by small molecules and viral RNA mimics. Cell Host Microbe, 2023, 31(7):1154-1169.e10. PMID: 37339625.
Wang, Z.; Liu, J.; Chen, H.; Qiu, X.; Xie, L.; Kaniskan, H. Ü.; Chen, X.; Jin, J.*; Wei, W.*; Telomere Targeting Chimera Enables Targeted Destruction of Telomeric Repeat-Binding Factor Proteins. Journal of the American Chemical Society. 2023, 145(19):10872-10879. PMID: 37141574.
Yu, X.; Wang, J.; Gong, W.; Ma, A.; Shen, Y.; Zhang, C.; Liu, X.; Cai, L.; Liu, J.; Wang, G. G.*; Jin, J.*; Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader. Oncogene, 2023, 42(13):994-1009. PMID: 36747009.
Park, K. S.; Qin, L.; Kabir, M.; Luo, K.; Dale, B.; Zhong, Y.; Kim, A.; Wang, G. G.; Kaniskan, H. Ü.; Jin, J*; Targeted Degradation of PRC1 Components, BMI1 and RING1B, via a Novel Protein Complex Degrader Strategy. Advanced science (Weinheim, Baden-Württemberg, Germany). 2023, 10(10):e2205573. PMID: 36737841.
Sun, N.; Kabir, M.; Lee, Y.; Xie, L.; Hu, X.; Velez, J.; Chen, X.; Kaniskan, H. Ü.*; & Jin, J*; Discovery of the First Lactate Dehydrogenase Proteolysis Targeting Chimera Degrader for the Treatment of Pancreatic Cancer. Journal of Medicinal Chemistry. 2023, 66(1):596-610. PMID: 36538511.
Marcellino, B. K.; Yang, X.; Ümit Kaniskan, H.; Brady, C.; Chen, H.; Chen, K.; Qiu, X.; Clementelli, C.; Herschbein, L.; Li, Z.; Elghaity-Beckley, S.; Arandela, J.; Kelly, B.; Hoffman, R.; Liu, J.; Xiong, Y.; Jin, J.*; Shih, A. H.*; An MDM2 degrader for treatment of acute leukemias. Leukemia, 2023, 37(2):370-378. PMID: 36309559
For papers published before 2023, please see Dr. Jin’s full publication list